Adam J. Gadzinski, MD, MS, on Study Results Assessing the Impact of Telemedicine on Patient-Reported Outcomes

Video

The study was designed to determine the impact of a rurally focused telemedicine program on patient outcomes.

In a study presented at the Society of Urologic Oncology 21st Annual Meeting, researchers sought to determine the impact of a rurally focused telemedicine program on patient outcomes in the urologic oncology outpatient clinic at the University of Washington Medical Center (UWMC).

In an interview with CancerNetwork®, Adam J. Gadzinski, MD, MS, urologic oncology fellow and an acting instructor of Urologic Oncology at the Urology Clinic at UWMC, discussed the findings from this study.

Transcription:

So, what we found is that overall patient satisfaction was generally the same between both in person and telemedicine visits. But, no surprises, telemedicine didn't require essentially any travel, and at the University of Washington we tend to be a referral center for the state of Alaska and some of the other Pacific Northwest states, so some of our patients were spending a tremendous amount of money just to come and see us for outpatient visit appointments. And of our in-person visits, we found that almost 10% were spending over $1000 to come and see us in person, not to have surgery, just for an office visit; and telemedicine eliminated essentially all of those travel costs.

Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Related Content